Owkin Valuation, Funding & Investors
Owkin is valued at $1B as of November 2021.
Last Owkin valuation
$1B
Series B · Nov 2021
Last Owkin funding round
$50M
Series B · Jun 2022
Cumulative funding Owkin raised
$304M
across 8 funding rounds
Key investors in Owkin
GV
Cathay Innovation
NJF Capital
Bpifrance
Plug and Play
F-Prime
About Owkin
Owkin is a Paris-headquartered AI company with offices in New York and London, founded in 2016, that accelerates drug discovery and clinical trials using federated learning. It partners with Sanofi and Servier to analyze siloed biomedical data for cancer treatments, identifying drug candidates and diagnostic tools while preserving patient privacy. The company raised over $255 million, achieving unicorn status in 2021 via a $180 million Sanofi investment.
Founded
2016
HQ
New York City, NYWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Valuation
$1B (Nov 2021)
Owkin Valuation
Owkin is currently valued at $1B, based on its Series B in November 2021.
The $180M round was led by Sanofi.
Owkin valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Nov 2021 | Series B | $1B |
Owkin Funding History
Owkin has raised a total of $304M across 8 funding rounds.
Owkin's first fundraising round was a $2M seed round in October 2016. The most recent completed round was a $50M Series B in June 2022.
Owkin funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jun 2022 | Series B | Bristol-Myers Squibb (lead) | $50M | - | - |
| Nov 2021 | Series B | Sanofi (lead) | $180M | $1B | Owkin, a Paris-based AI and precision medicine company founded in 2016 by Thomas Clozel and Gilles Wainrib, develops predictive biomedical AI models using federated learning to analyze multimodal patient data from hospitals and research centers while preserving privacy. The company builds comprehensive histology and genomic cancer databases and optimizes clinical trial design by detecting predictive biomarkers. On November 18, 2021, Sanofi invested $180 million in equity, making Owkin a unicorn with a post-money valuation of $1 billion, marking the opening of its Series B round after prior fundraising totaling around $144 million including a $70 million Series A. This investment coincided with a strategic multi-year collaboration between Owkin and Sanofi, involving discovery and development programs for four cancers: non-small cell lung cancer, triple-negative breast cancer, mesothelioma, and multiple myeloma. Sanofi committed $90 million over three years for the collaboration, plus milestone-based payments, to leverage Owkin's platform for identifying biomarkers, building predictive models, and forecasting treatment responses to bolster its oncology portfolio. The deal positions Sanofi to access Owkin's global network of decentralized datasets from academic medical centers. Owkin has published research in journals like Nature Medicine and uses its technology for drug discovery and development. The partnership accelerates Owkin's oncology ambitions and Sanofi's precision medicine efforts. This funding brought Owkin's total raised to over $324 million, establishing a long-term alliance in AI-driven cancer research. |
| Jul 2020 | Series A | Bpifrance (lead); Mubadala (lead) | $18M | - | Owkin is a French-American startup founded in 2016 by Thomas Clozel and Gilles Wainrib, applying federated learning and machine learning to medical research. The company builds a global research network connecting data scientists, clinicians, researchers, and pharmaceutical companies on a privacy-preserving platform that keeps data secure without sharing patient information. Its work has been published in top journals like Nature Medicine, and it collaborates with major cancer centers and pharma firms in Europe and the US. On June 30, 2020, Owkin closed an $18 million extension to its Series A round from Mubadala Capital and Bpifrance's Large Venture fund, bringing the total Series A to $70 million. This followed prior Series A investments starting in 2018 from backers including Cathay Innovation, MACSF, GV, F-Prime Capital, Eight Roads, Frst, and NJF Capital. Bpifrance had made an earlier investment in the round just weeks prior, underscoring its commitment. The funding aims to accelerate the federation of Owkin's research ecosystem, expand collaborations between researchers and the pharmaceutical industry, and deploy AI at scale in biomedical research. Plans include geographic expansion into Germany and the Middle East. The platform addresses data privacy challenges, contrasting with cloud storage solutions from big tech, and gained interest for COVID-19 research. Later developments include a 2021 $180 million investment from Sanofi, achieving unicorn status over $1 billion valuation, and a $90 million three-year R&D contract in oncology. |
| May 2020 | Series A | Bpifrance (lead); Plug and Play; GV; F-Prime; MACSF; Eight Roads Ventures; Cathay Innovation | $25M | - | Owkin is a Paris and New York-based AI company applying machine learning and federated learning to medical research, enabling collaborative analysis across hospitals, clinicians, researchers, and pharma companies while preserving data privacy and avoiding direct data sharing. The platform connects data scientists with healthcare providers to accelerate drug discovery, diagnostics, and treatments, with publications in journals like Nature Medicine and partnerships with major cancer centers and pharmaceutical firms. In May 2020, Owkin raised $25 million in an extension of its Series A round led by Bpifrance, with participation from Cathay Innovation, MACSF, and existing investors GV, F-Prime Capital, and Eight Roads Ventures. This followed an initial Series A in 2018 and brought total funding at the time to around $55 million. In July 2020, Owkin secured an additional $18 million from Bpifrance and Mubadala Capital Ventures as a further Series A extension, pushing cumulative funding to approximately $73 million. The funds supported expansion of AI infrastructure, diagnostics capabilities, geographic growth into Germany and the Middle East, and collaborative research amid rising interest in COVID-19 applications. Owkin continued growing post-2020, striking multi-year deals exceeding $100 million with pharma giants and becoming a unicorn through Sanofi's 2021 investment. |
| Mar 2019 | Series A | Eight Roads Ventures (lead); F-Prime (lead); GV; NJF Capital; Cathay Innovation | $13M | - | Owkin raised $13 million in a Series A funding round on March 7, 2019, led by F-Prime Capital and Eight Roads Ventures, with participation from GV, Cathay Innovation, and NJF Capital. The funding aimed to expand research collaborations and data access for its machine learning technologies in medical research. Founded in 2016, Owkin develops AI algorithms to predict treatment outcomes and disease evolution, enabling federated learning on hospital data while preserving patient privacy. Owkin's platform supports drug discovery and clinical trial design by identifying multimodal biomarkers and high-value patient subgroups. The company combines life science and machine learning expertise to make drug development more targeted and cost-effective. This round followed prior investments, including from GV in May 2018, bringing total funding at the time to around $18 million. |
| May 2018 | Series A | GV (lead) | $5M | - | Owkin raised $5 million in a Series A round in May 2018 led by GV (Google Ventures). This was part of an extended Series A financing that included prior $11 million in January 2018 from Otium Capital and later extensions. The funding supported development of AI decision-making tools for biopharma. Owkin develops AI technology for precision medicine, focusing on biomedical research, drug discovery, and diagnostics using federated learning to analyze patient data without sharing it directly. |
| Jan 2018 | Series A | Otium Capital (lead); Plug and Play; NJF Capital; Cathay Innovation | $11M | - | Owkin raised $11 million in a Series A funding round on January 16, 2018, led by Otium Capital with participation from Cathay Innovation, Plug and Play, and NJF Capital, bringing total funding to $13.1 million. The company develops OWKIN Socrates, a predictive analytics platform using transfer learning to analyze patient data, predict treatment outcomes, and accelerate drug discovery while respecting data privacy. Funds were allocated to expand the platform, build partnerships with healthcare organizations, and support internal growth. Bruno Raillard from Otium Capital joined the board of directors. |
| Oct 2016 | Seed | Brent Hoberman; Shana Fisher; NJF Capital; Idorsia; Jorg Mohaupt | $2M | - | - |
Who has invested in Owkin?
16 investors have backed Owkin across its funding rounds, including GV, Cathay Innovation, NJF Capital, Bpifrance, Plug and Play and F-Prime.
Lead investors include Bristol-Myers Squibb, Sanofi, Bpifrance, Mubadala, Eight Roads Ventures and 3 other investors.
Owkin Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| San Francisco, CA | 3 | Lead | May 2018 | |
 London | 3 | Participant | Oct 2016 | |
| San Francisco, CA | 3 | Participant | Jan 2018 | |
| San Francisco, CA | 2 | Participant | Jan 2018 | |
| United States | 2 | Lead | Mar 2019 | |
 Paris | 2 | Lead | May 2020 | |
| London | 2 | Lead | Mar 2019 | |
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>){kind=small} Brent Hoberman | London | 1 | Participant | Oct 2016 |
| Paris | 1 | Participant | May 2020 | |
| Shana Fisher | New York City, NY | 1 | Participant | Oct 2016 |
| Paris | 1 | Lead | Jan 2018 | |
| New York City, NY | 1 | Lead | Jun 2022 | |
| Paris | 1 | Lead | Nov 2021 | |
This data is available for Pro users. Sign up to see all 16 Owkin investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialInvestments by Owkin
Owkin has invested in 2 companies to date.
Latest investment by Owkin was on February 20th 2024. Owkin invested in Bioptimus in their $35M Seed round.
Latest Investments by Owkin
| Description | Bioptimus is a Paris-based AI biotechnology firm building foundation models for biology that integrate multi-scale data from proteins to organisms. Its Bioptimus platform combines proprietary datasets, high-performance computing, and machine learning to model cellular processes and predict drug responses. Launched in 2023, the company raised €34 million in seed funding from investors including Merian Ventures, targeting precision medicine and synthetic biology advancements. | Tribun Health is a Paris-headquartered developer of digital pathology software tailored for oncology diagnostics. The company offers Orifarm, a platform that processes whole slide images from scanners, supporting histopathology workflows in laboratories and pharmaceutical research. Tribun Health enables pathologists to annotate slides, run AI algorithms for tumor detection, and collaborate remotely via cloud access. Founded in 2015, it serves European diagnostic centers and biotech firms focused on cancer therapies, with integrations for major slide scanners from vendors like Leica and Philips. |
| HQ Country | | |
| HQ City | Paris | Châtillon |
| Deal Date | 20 Feb 2024 | 5 Sep 2023 |
| Round | Seed | Series B |
| Raised | $35M | $16M |
| Investors | Frst; Hummingbird Ventures; Top Harvest Capital; Anthony Sides; Sofinnova Partners; Bpifrance; NJF Capital; Headline; Cathay Innovation | Vivalto Partners; LBO France; Bpifrance |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Owkin investments and their VC round multiples. Start Free Trial | ||
Owkin Competitors
Owkin competitors include listed companies like ODDITY Tech and ZoomInfo, and private ones like Aibee, Enveda Biosciences, Meero and MegaRobo.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
 Beijing | Private | - | - | $1B | - | |
| Boulder, CO | Private | - | - | $1B | - | |
| France | Private | - | - | $1B | - | |
| China | Private | - | - | $1B | - | |
| United States | Publicly listed | $810M | $131M | $889M | 1.8x | |
| United States | Publicly listed | $1.2B | $326M | $1.2B | 2.1x |
Owkin Public Comps
Owkin is still privately-owned, but its public comps include iFLYHealth, ODDITY Tech, Braiin, ZoomInfo, Beijing Haitian Ruisheng, Beijing Deep Glint Tech, Shenzhen Sunwin, Fractal Analytics, BigBear.ai and Unisound Ai Technology.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $136M | ($7M) | 7.7x | 6.2x | (150.8x) | (144172.5x) | |||
| $810M | $131M | 1.5x | 1.8x | 9.6x | 18.3x | |||
| $73M | ($15M) | 15.8x | 13.0x | (76.1x) | 89.6x | |||
| $1.2B | $326M | 2.0x | 2.1x | 7.8x | 5.1x | |||
| $56M | $5M | 13.8x | 14.0x | 160.9x | - | |||
| $23M | ($29M) | 25.1x | 8.7x | (19.8x) | (80.2x) | |||
| $20M | ($147M) | 37.7x | - | (5.0x) | - | |||
| $344M | $50M | 3.7x | 3.4x | 25.8x | 21.0x | |||
This data is available for Pro users. Sign up to see all Owkin competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Owkin
| When was Owkin founded? | Owkin was founded in 2016. |
| Where is Owkin headquartered? | Owkin is headquartered in New York City, NY, United States. |
| Is Owkin publicly listed? | No, Owkin is a private, VC-backed company. |
| What is Owkin's valuation? | Owkin was last valued at $1B in its Series B in November 2021. |
| How much funding has Owkin raised? | Owkin has raised $304M across 8 funding rounds. |
| What was Owkin's last funding round? | Owkin's last funding round was a $50M Series B in June 2022, led by Bristol-Myers Squibb. |
| Who are Owkin's investors? | Owkin's investors include GV, NJF Capital, Cathay Innovation, Plug and Play, F-Prime, Bpifrance, Eight Roads Ventures, Brent Hoberman, MACSF, Shana Fisher and 6 others. |
| Which companies are comparable to Owkin? | Companies comparable to Owkin include Aibee, Enveda Biosciences, Meero, MegaRobo, ODDITY Tech and ZoomInfo. |
| How many companies has Owkin invested in? | Owkin has invested in 2 companies, including Bioptimus and Tribun Health. |
| What was Owkin's last investment? | In February 2024, Owkin invested in Bioptimus' $35M seed round alongside Frst, Hummingbird Ventures, Top Harvest Capital and 6 other investors. |
See companies similar to Owkin
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.